NYSE:SNY - Sanofi News Headlines

Sign in or create an account to add this stock to your watchlist.
$45.00 +0.06 (+0.13 %)
(As of 11/20/2018 11:02 AM ET)
Previous Close$44.94
Today's Range$44.67 - $45.02
52-Week Range$37.43 - $46.25
Volume282,230 shs
Average Volume1.54 million shs
Market Capitalization$113.11 billion
P/E Ratio14.38
Dividend Yield2.67%
Beta0.7

Headlines

Sanofi (NYSE SNY) News Headlines

Source:
DateHeadline
Sanofi (SNY) Receives Daily Coverage Optimism Score of 1.17Sanofi (SNY) Receives Daily Coverage Optimism Score of 1.17
www.americanbankingnews.com - November 20 at 5:54 AM
$0.64 EPS Expected for Sanofi SA (SNY) This Quarter$0.64 EPS Expected for Sanofi SA (SNY) This Quarter
www.americanbankingnews.com - November 17 at 5:20 AM
Sanofi (SNY) Receiving Somewhat Positive Media Coverage, Report ShowsSanofi (SNY) Receiving Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - November 16 at 10:20 PM
European advisory group backs Sanofis fexinidazole for sleeping sicknessEuropean advisory group backs Sanofi's fexinidazole for sleeping sickness
seekingalpha.com - November 16 at 8:25 AM
Sanofi-Aventis: CHMP Adopts Positive Scientific Opinion Of FexinidazoleSanofi-Aventis: CHMP Adopts Positive Scientific Opinion Of Fexinidazole
www.nasdaq.com - November 16 at 8:25 AM
Somewhat Positive Press Coverage Unlikely to Impact Sanofi (SNY) Share PriceSomewhat Positive Press Coverage Unlikely to Impact Sanofi (SNY) Share Price
www.americanbankingnews.com - November 12 at 8:10 PM
ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any causeODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause
finance.yahoo.com - November 11 at 8:30 AM
Regeneron (REGN), Sanofi (SNY) announce NEJM published positive detailed results from Praluent cardiovascular outcomes trialRegeneron (REGN), Sanofi (SNY) announce NEJM published positive detailed results from Praluent cardiovascular outcomes trial
www.streetinsider.com - November 9 at 8:35 AM
Sanofi SA (SNY) Receives Average Rating of "Hold" from AnalystsSanofi SA (SNY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 9 at 1:31 AM
Somewhat Favorable Press Coverage Very Unlikely to Affect Sanofi (SNY) Stock PriceSomewhat Favorable Press Coverage Very Unlikely to Affect Sanofi (SNY) Stock Price
www.americanbankingnews.com - November 8 at 9:14 PM
Sanofi (SNY) Price Target Raised to $50.00 at ArgusSanofi (SNY) Price Target Raised to $50.00 at Argus
www.americanbankingnews.com - November 8 at 6:01 PM
Regulus Therapeutics (RGLS) Announces Restructuring of Sanofi (SNY) CollaborationRegulus Therapeutics (RGLS) Announces Restructuring of Sanofi (SNY) Collaboration
www.streetinsider.com - November 7 at 8:31 AM
Sanofi (SNY) Getting Somewhat Favorable Media Coverage, Analysis FindsSanofi (SNY) Getting Somewhat Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - November 4 at 11:23 AM
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in FocusPharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
www.zacks.com - November 2 at 8:29 AM
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store?
finance.yahoo.com - November 2 at 8:29 AM
Sanofi (SNY) Announces  Earnings ResultsSanofi (SNY) Announces Earnings Results
www.americanbankingnews.com - November 1 at 1:59 PM
Sanofi (SNY) Upgraded to "Equal Weight" at BarclaysSanofi (SNY) Upgraded to "Equal Weight" at Barclays
www.americanbankingnews.com - November 1 at 12:47 PM
Sanofi expands Insulins VALyou Savings Program, helping more people living with diabetesSanofi expands Insulins VALyou Savings Program, helping more people living with diabetes
finance.yahoo.com - November 1 at 8:20 AM
Sanofis (SNY) Neutral Rating Reaffirmed at JPMorgan Chase & Co.Sanofi's (SNY) Neutral Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - October 31 at 3:33 PM
Stock Traders Buy High Volume of Call Options on Sanofi (SNY)Stock Traders Buy High Volume of Call Options on Sanofi (SNY)
www.americanbankingnews.com - October 31 at 9:03 AM
Sanofi: 3Q Earnings SnapshotSanofi: 3Q Earnings Snapshot
finance.yahoo.com - October 31 at 8:33 AM
Sanofis (SNY) says FDA granted priority review for its dengue vaccine candidateSanofi's (SNY) says FDA granted priority review for its dengue vaccine candidate
www.streetinsider.com - October 31 at 8:33 AM
Sanofi Q3 revenues up 4%; non-GAAP EPS up 8%; shares up 3% premarketSanofi Q3 revenues up 4%; non-GAAP EPS up 8%; shares up 3% premarket
seekingalpha.com - October 31 at 8:33 AM
Sanofi Sees Unusually Large Options Volume (SNY)Sanofi Sees Unusually Large Options Volume (SNY)
www.americanbankingnews.com - October 31 at 8:12 AM
A Closer Look At Sanofi’s (EPA:SAN) Uninspiring ROEA Closer Look At Sanofi’s (EPA:SAN) Uninspiring ROE
finance.yahoo.com - October 30 at 8:32 AM
Esperion stock surges 15% on late-stage results for cholesterol drugEsperion stock surges 15% on late-stage results for cholesterol drug
finance.yahoo.com - October 29 at 8:45 AM
Drugmaker Amgen just cut the price of its $14000-a-year medication by 60%Drugmaker Amgen just cut the price of its $14000-a-year medication by 60%
www.businessinsider.com - October 25 at 8:31 AM
Adhesion Barrier Market Size Worth $1.13 Billion by 2026 | CAGR 7.1%: Grand View Research, Inc.Adhesion Barrier Market Size Worth $1.13 Billion by 2026 | CAGR 7.1%: Grand View Research, Inc.
www.prnewswire.com - October 24 at 8:33 AM
Breakthroughs in Breast Cancer ResearchBreakthroughs in Breast Cancer Research
finance.yahoo.com - October 23 at 4:57 PM
FDA OKs Regeneron and Sanofis Dupixent for asthmaFDA OKs Regeneron and Sanofi's Dupixent for asthma
seekingalpha.com - October 21 at 8:40 AM
FDA approves asthsma indication for Dupixent® (dupilumab)FDA approves asthsma indication for Dupixent® (dupilumab)
finance.yahoo.com - October 20 at 8:28 AM
Sanofi Gets Positive CHMP Opinion For Dengue Vaccine - Quick FactsSanofi Gets Positive CHMP Opinion For Dengue Vaccine - Quick Facts
www.nasdaq.com - October 19 at 8:36 AM
Biotech Analysis Central Pharma News: Regenerons Results, BMYs Failure, Novartis FDA RejectionBiotech Analysis Central Pharma News: Regeneron's Results, BMY's Failure, Novartis' FDA Rejection
seekingalpha.com - October 19 at 8:36 AM
Sanofi (SNY) announces positive CHMP opinion for dengue vaccineSanofi (SNY) announces positive CHMP opinion for dengue vaccine
www.streetinsider.com - October 19 at 8:36 AM
Dupixent: Top-Down And Bottom-Up Perspectives On The NewsDupixent: Top-Down And Bottom-Up Perspectives On The News
seekingalpha.com - October 17 at 8:33 AM
Canadians are invited to join the conversation: Raise Your Hand for DiabetesCanadians are invited to join the conversation: Raise Your Hand for Diabetes
finance.yahoo.com - October 17 at 8:33 AM
Regenerons Dupixent successful in late-stage rhinosinusitis studiesRegeneron's Dupixent successful in late-stage rhinosinusitis studies
seekingalpha.com - October 16 at 8:33 AM
10 Safer Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends
seekingalpha.com - October 16 at 8:33 AM
Sanofi, Regeneron say late-stage Dupixent trials show positive resultsSanofi, Regeneron say late-stage Dupixent trials show positive results
finance.yahoo.com - October 16 at 8:33 AM
[$$] European Corporate News Roundup[$$] European Corporate News Roundup
finance.yahoo.com - October 16 at 8:33 AM
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polypsDupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
finance.yahoo.com - October 16 at 8:33 AM
What to Do When You Cant Afford Your Chronic Disease MedicationWhat to Do When You Can't Afford Your Chronic Disease Medication
finance.yahoo.com - October 11 at 4:46 PM
Keeping Women In STEM Careers: Looking to Data For AnswersKeeping Women In STEM Careers: Looking to Data For Answers
finance.yahoo.com - October 9 at 4:51 PM
Lexicon Likely Looking At Even More Competition In Type 1 DiabetesLexicon Likely Looking At Even More Competition In Type 1 Diabetes
seekingalpha.com - October 5 at 4:49 PM
Sangamo Therapeutics: Analysts Expect 88% Upside PotentialSangamo Therapeutics: Analysts Expect 88% Upside Potential
finance.yahoo.com - October 5 at 8:30 AM
Cancer Investing Highlight: Another One Joins The Big Immunotherapy ContestCancer Investing Highlight: Another One Joins The Big Immunotherapy Contest
seekingalpha.com - October 2 at 8:31 AM
How Libtayos Approval May Help Cure Regenerons Remaining IllsHow Libtayo's Approval May Help Cure Regeneron's Remaining Ills
seekingalpha.com - October 1 at 4:51 PM
Sanofi completes divestiture of Zentiva to AdventSanofi completes divestiture of Zentiva to Advent
seekingalpha.com - October 1 at 8:27 AM
Sanofi, Regeneron have skin-cancer drug approvedSanofi, Regeneron have skin-cancer drug approved
www.marketwatch.com - September 29 at 8:18 AM
FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinomaFDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
finance.yahoo.com - September 28 at 4:54 PM
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Featured Article: Quiet Period

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel